Ophthalmology not a priority?

Quote

Looks like Oyster Point just realized there is no room for a dry eye tear in a nasal delivery spray. They had zero data and didn't even treat the disease state. What were they thinking? I wonder if Viatris will can the sales force.

Xiidra is the only DED medication left standing. Still going........
 


anonymous said:
Looks like Oyster Point just realized there is no room for a dry eye tear in a nasal delivery spray. They had zero data and didn't even treat the disease state. What were they thinking? I wonder if Viatris will can the sales force.

Xiidra is the only DED medication left standing. Still going........
Click to expand...

idk what OP was thinking with a nasal spray for DED. Just dumb. Additionally idk how much longer Xiidra can keep going (and let’s be honest it’s not even going strong) in a dying space. No docs care about DED anymore.
 


I had a doctor tell me last week that they have 2 types of dry eye patients. The first will not want a script and are happy to use AT all day long. The rest are looking for something beyond a tear or drop. They want something new and that’s why he’s investing in new IPL and other equipment. He can also make more money going that route so that’s what he’s pushing
 










They tried having neuroscience division do that at Shire back in the day and it was a horrible mess. Doctors were calling reps telling them they only needed one rep. It was awful. Leadership really needs to ask the field for advice on what’s worked/what’s not worked.

ohh wait all they care about is metrics…metrics..metrics…this is the worst culture EVER!
 


Not sure if it’s true or not but if it is, ONCE AGAIN leadership thinks more bodies calling on customers is going to make a big difference. If they are deploying a contract team I hope it’s in lower tier offices for reach as that may actually help. If it’s the customers we already see, bad idea
 






















anonymous said:
Novartis bought Xiidra in 2019 for 3.4B. Sales haven’t grown from what Shire did, a little over 400M/YR. Europe didn’t get approved. Eventually we will have to cut bait on a bad tasting artificial tear.
Click to expand...

Novartis’ ophthalmology strategy has been a series of failures:
1) 2019, Xiidra, acquired from Shire for $5bn, currently selling: ~400m a year
2) 2021, GT005 (gene therapy, phase 2 at that time), acquired from Gyroscope, currently selling: 0
3) 2020, preclinical gene therapy asset, acquired from Vedere Bio (made a lot of people rich) for 450m, currently selling: 0
4) 2021, preclinical gene therapy asset, acquired from Arctos Medical (made a lot of people rich again) for ??? (Prob 500m), currently selling: 0


So why is Novartis selling Ophtha for what it thinks can be up to $5bn? My guess is that they are trying to recoup the loss it has incurred from buying all these assets at significantly overvalued price tag. So fast forward 2 years from 2021 to 2023, OPHTH is NOT a strategic focus anymore. I’m not a shareholder of Novartis but if I were I’d hold the board accountable.
 



Write your reply...
Top Bottom
Back
Quote